Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Pajares, Bella; Pollán, Marina; Martín, Miguel; Mackey, John R; Lluch, Ana; Gavila, Joaquín; Vogel, Charles; Ruiz-Borrego, Manuel; Calvo, Lourdes; Pienkowski, Tadeusz; Rodríguez-Lescure, Álvaro; Seguí, Miguel Angel; Tredan, Olivier; Antón, Antonio; Ramos, Manuel; Cámara, María del Carmen; Rodríguez-Martín, César; Carrasco, Eva; Alba, Emilio

doi:10.1186/bcr3572

Table 2 Multivariate Cox proportional hazards regression analysis of effect of BMI and each study variable on overall mortality, breast cancer mortality, and recurrence in basic models (adjusted for study and treatment regimen only)

From: Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

		Overall mortality				Breast cancer mortality				Recurrence
Variable	Number	Events	HR^a	95% CI	P-value	Events	HR	95% CI	P-value	Events	HR	95% CI	P-value
Body mass index, k/m ²
<18.5	66	11	1.08	0.59, 1.98	0.796	9	1.06	0.54, 2.06	0.864	12	0.88	0.49, 1.56	0.650
18.5 to 24.9	2,297	312	1.00			256	1.00			419	1.00
25.0 to 29.9	1,944	265	0.99	0.84, 1.16	0.880	220	1.00	0.83, 1.20	0.984	348	0.95	0.83, 1.10	0.522
30.0 to 34.9	945	139	1.07	0.87, 1.30	0.526	111	1.04	0.83, 1.29	0.757	173	0.98	0.82, 1.17	0.831
≥35.0	431	91	1.47	1.16, 1.85	0.001	68	1.32	1.01, 1.72	0.043	95	1.14	0.91, 1.42	0.249
				P for trend	0.002			P for trend	0.074			P for trend	0.287
Age at diagnosis, years
23 to 44	1,667	276	1.00			245	1.00			416	1.00
45 to 54	2,036	228	0.66	0.55, 0.78	<0.001	187	0.61	0.50, 0.73	<0.001	296	0.54	0.47. 0.63	<0.001
55 to 64	1,443	202	0.92	0.77, 1.11	0.380	156	0.81	0.66, 0.99	0.036	231	0.66	0.56, 0.78	<0.001
65 to 76	537	112	1.41	1.13, 1.76	0.002	76	1.08	0.83, 1.39	0.583	104	0.81	0.65, 1.00	0.049
				P for trend	0.030			P for trend	0.655			P for trend	<0.001
Menopausal status
Postmenopausal	2,661	421	1.00			322	1.00			461	1.00
Premenopausal	3022	397	0.75	0.66, 0.86	<0.001	342	0.85	0.73, 0.98	0.031	586	1.05	0.93, 1.19	0.415
Histology
Ductal	4,809	700	1.00			571	1.00			892	1.00
Lobular	510	66	0.79	0.62, 1.02	0.072	52	0.76	0.57, 1.01	0.062	96	0.92	0.75, 1.14	0.446
Mixed	364	52	0.92	0.69, 1.22	0.561	41	0.89	0.65, 1.22	0.456	59	0.82	0.63, 1.07	0.150
Others	389	66	2.32	1.54, 3.49	<0.001	55	2.92	1.79, 4.75	<0.001	87	2.01	1.44, 2.83	0.000
Histological grade
1	499	35	1.00			23	1.00			55	1.00
2	2,404	277	2.09	1.47, 2.97	<0.001	217	2.51	1.63, 3.87	<0.001	382	1.84	1.39, 2.45	<0.001
3	2,391	440	3.70	2.62, 5.23	<0.001	369	4.77	3.13, 7.28	<0.001	523	2.82	2.13, 3.72	<0.001
Unknown	389	66	2.32	1.54, 3.49	<0.001	55	2.92	1.79, 4.75	<0.001	87	2.01	1.44, 2.83	<0.001
Pathologic primary tumor size
T1	2,794	249	1.00			194	1.00			349	1.00
T2	2,665	510	1.96	1.68, 2.28	<0.001	417	2.03	1.71, 2.41	<0.001	628	1.78	1.57, 2.04	<0.001
T3	224	59	2.14	1.61, 2.84	<0.001	53	2.39	1.76, 3.25	<0.001	70	1.98	1.53, 2.57	<0.001
				P for trend	<0.001			P for trend	<0.001			P for trend	<0.001
Estrogen receptor/progesterone receptor
Both negative	1,502	300	1.00			256	1.00			349	1.00
Any of them positive	4,132	503	0.49	0.43, 0.57	<0.001	394	0.45	0.38, 0.53	<0.001	679	0.59	0.51, 0.67	<0.001
Unknown	49	15	0.77	0.46, 1.31	0.338	14	0.82	0.48, 1.41	0.471	19	1.00	0.63, 1.59	0.998
Human epidermal growth factor-2 status
Negative	4,055	518	1.00			407	1.00			660	1.00
Positive	830	182	1.34	1.13, 1.59	0.001	153	1.42	1.18, 1.71	<0.001	223	1.38	1.18, 1.61	<0.001
Unknown	798	118	1.04	0.85, 1.28	0.690	104	1.17	0.94, 1 · 45	0.172	164	1.14	0.95, 1.36	0.157
Type of surgery
Mastectomy	2,621	512	1.00			420	1.00			633	1.00
Conservative	3,062	306	0.71	0.61, 0.82	<0.001	244	0.71	0.60, 0.83	<0.001	414	0.73	0.65, 0.83	<0.001
Hormonotherapy
No	1,439	314	1.00			263	1.00			354	1.00
Yes	4,045	451	0.42	0.36, 0.48	<0.001	356	0.39	0.33, 0.46	<0.001	622	0.51	0.45, 0.58	<0.001
Unknown	199	53	0.79	0.58, 1.06	0.112	45	0.77	0.56, 1.07	0.120	71	1.05	0.81, 1.37	0.692
Initial undertreatment (first dose <85%)
No	5,532	648	1.00
Yes	151	16	1.01	0.78,1.31	0.932	16	1.06	0.64, 1.75	0.820	20	0.84	0.54, 1.31	0.447
Overall undertreatment (dose <85%)
None	5,083	725	1.00			599	1.00			943	1.00
Epirubicine <85%	78	24	1.55	1.02, 2.36	0.040	20	1.56	0.98, 2.47	0.059	25	1.29	0.86, 1.93	0.226
Cyclophosphamide <85%	296	56	1.28	0.98, 1.69	0.074	41	1.13	0.82, 1.56	0.446	63	1.14	0.88, 1.47	0.323
Fluorouracil <85%	181	33	1.20	0.84, 1.70	0.316	23	1.01	0.66, 1.53	0.977	34	0.98	0.69, 1.38	0.888
Doxorubicin <85%	226	38	1.30	0.93, 1.81	0.119	27	1.12	0.76, 1.65	0.576	42	1.13	0.82, 1.54	0.451
Docetaxel <85%	176	32	1.08	0.74, 1.57	0.696	24	0.96	0.62, 1.47	0.846	39	1.04	0.74, 1.46	0.814
Paclitaxel <85%	244	27	1.43	0.94, 2.18	0.092	16	1.05	0.62, 1.78	0.863	30	1.09	0.74, 1.61	0.662

^aHazard ratio, 95% CI and P-value adjusted for study and treatment regimen.

Back to article page